WO2000035956A1 - Anticorps monoclonal anti-vegf humain - Google Patents

Anticorps monoclonal anti-vegf humain Download PDF

Info

Publication number
WO2000035956A1
WO2000035956A1 PCT/JP1999/007074 JP9907074W WO0035956A1 WO 2000035956 A1 WO2000035956 A1 WO 2000035956A1 JP 9907074 W JP9907074 W JP 9907074W WO 0035956 A1 WO0035956 A1 WO 0035956A1
Authority
WO
WIPO (PCT)
Prior art keywords
vegf
monoclonal antibody
antibody
human
cells
Prior art date
Application number
PCT/JP1999/007074
Other languages
English (en)
Japanese (ja)
Inventor
Kenya Shitara
Mikito Ito
Nobuo Hanai
Junji Kanazawa
Tatsuya Tamaoki
Masabumi Shibuya
Original Assignee
Kyowa Hakko Kogyo Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Co., Ltd. filed Critical Kyowa Hakko Kogyo Co., Ltd.
Priority to AU16875/00A priority Critical patent/AU1687500A/en
Publication of WO2000035956A1 publication Critical patent/WO2000035956A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne un anticorps monoclonal anti-VEGF humain, qui inhibe la liaison du VEGF humain aux deux récepteurs KDR et Flt-1 correspondants, ce qui inhibe les fonctions de KDR et Flt-1 ainsi que diverses activités du VEGF humain.
PCT/JP1999/007074 1998-12-16 1999-12-16 Anticorps monoclonal anti-vegf humain WO2000035956A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU16875/00A AU1687500A (en) 1998-12-16 1999-12-16 Antihuman vegf monoclonal antibody

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP35714898 1998-12-16
JP10/357148 1998-12-16

Publications (1)

Publication Number Publication Date
WO2000035956A1 true WO2000035956A1 (fr) 2000-06-22

Family

ID=18452629

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1999/007074 WO2000035956A1 (fr) 1998-12-16 1999-12-16 Anticorps monoclonal anti-vegf humain

Country Status (2)

Country Link
AU (1) AU1687500A (fr)
WO (1) WO2000035956A1 (fr)

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1086705A1 (fr) * 1998-05-20 2001-03-28 Kyowa Hakko Kogyo Co., Ltd. Inhibiteurs de l'activite du facteur de croissance endothelial vasculaire (vegf)
JP2008067710A (ja) * 2003-09-10 2008-03-27 Warner-Lambert Co Llc Ｍ−ｃｓｆに対する抗体
EP2364732A1 (fr) 2006-03-22 2011-09-14 F. Hoffmann-La Roche AG Traitement antitumoral au moyen d'un anticorps contre le facteur de croissance endothélial vasculaire (vegf) et d'un anticorps contre le récepteur humain du facteur de croissance épitheliale de type 2 (her2)
WO2011117329A1 (fr) 2010-03-26 2011-09-29 F. Hoffmann-La Roche Ag Anticorps bispécifiques, bivalents anti-vegf/anti-ang-2
WO2012022747A1 (fr) 2010-08-17 2012-02-23 F. Hoffmann-La Roche Ag Thérapie de combinaison d'un anticorps afucosylé anti-cd20 avec un anticorps anti-vegf
EP2441472A1 (fr) 2006-08-21 2012-04-18 F. Hoffmann-La Roche AG Thérapie de tumeur avec anticorps anti-VEGF
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US9382323B2 (en) 2009-04-02 2016-07-05 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
US9567403B2 (en) 2013-08-06 2017-02-14 Bio-Thera Solutions, Ltd. Bispecific antibodies which bind EGFR and VEGF
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US9688758B2 (en) 2012-02-10 2017-06-27 Genentech, Inc. Single-chain antibodies and other heteromultimers
US9695233B2 (en) 2012-07-13 2017-07-04 Roche Glycart Ag Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases
US9879095B2 (en) 2010-08-24 2018-01-30 Hoffman-La Roche Inc. Bispecific antibodies comprising a disulfide stabilized-Fv fragment
US9890204B2 (en) 2009-04-07 2018-02-13 Hoffmann-La Roche Inc. Trivalent, bispecific antibodies
US9982036B2 (en) 2011-02-28 2018-05-29 Hoffmann-La Roche Inc. Dual FC antigen binding proteins
US9994646B2 (en) 2009-09-16 2018-06-12 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
US10106612B2 (en) 2012-06-27 2018-10-23 Hoffmann-La Roche Inc. Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
US10106600B2 (en) 2010-03-26 2018-10-23 Roche Glycart Ag Bispecific antibodies
US10138293B2 (en) 2007-12-21 2018-11-27 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US10323099B2 (en) 2013-10-11 2019-06-18 Hoffmann-La Roche Inc. Multispecific domain exchanged common variable light chain antibodies
WO2019129677A1 (fr) 2017-12-29 2019-07-04 F. Hoffmann-La Roche Ag Anticorps anti-vegf et procédés d'utilisation
US10611825B2 (en) 2011-02-28 2020-04-07 Hoffmann La-Roche Inc. Monovalent antigen binding proteins
US10633457B2 (en) 2014-12-03 2020-04-28 Hoffmann-La Roche Inc. Multispecific antibodies
US11421022B2 (en) 2012-06-27 2022-08-23 Hoffmann-La Roche Inc. Method for making antibody Fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
US11618790B2 (en) 2010-12-23 2023-04-04 Hoffmann-La Roche Inc. Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0787742A1 (fr) * 1995-08-21 1997-08-06 MITSUI TOATSU CHEMICALS, Inc. Anticorps monoclonal humain contre le VEGF
JPH10245347A (ja) * 1997-02-28 1998-09-14 Toagosei Co Ltd 体液再貯留抑制剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0787742A1 (fr) * 1995-08-21 1997-08-06 MITSUI TOATSU CHEMICALS, Inc. Anticorps monoclonal humain contre le VEGF
JPH10245347A (ja) * 1997-02-28 1998-09-14 Toagosei Co Ltd 体液再貯留抑制剤

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANTHONY P. ADAMIS ET AL.: "Inhibition of Vascular Endothelial Growth Factor Prevents Retinal Ischemia-Associated Iris Neovascularization in a Nonhuman Primate", ARCHIVES OF OPHTHALMOLOGY, vol. 114, no. 1, January 1996 (1996-01-01), pages 66 - 71, XP002924364 *
K. JIN KIM ET AL.: "Inhibition of vascular endothelial growth factor-induced angiogenesis supresses tumour growth in vivo", NATURE, vol. 362, 29 April 1993 (1993-04-29), pages 841 - 844, XP002924366 *
OSTAP MELNYK ET AL.: "Vascular Endothelial Growth Factor Promotes Tumor Dissemination by a Mechanism Distinct from Its Effect on Primary Tumor Growth", CANCER RESEARCH, vol. 56, no. 4, 15 February 1996 (1996-02-15), pages 921 - 924, XP002924365 *

Cited By (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1086705A1 (fr) * 1998-05-20 2001-03-28 Kyowa Hakko Kogyo Co., Ltd. Inhibiteurs de l'activite du facteur de croissance endothelial vasculaire (vegf)
EP1086705A4 (fr) * 1998-05-20 2002-02-06 Kyowa Hakko Kogyo Kk Inhibiteurs de l'activite du facteur de croissance endothelial vasculaire (vegf)
US10280219B2 (en) 2003-09-10 2019-05-07 Amgen Fremont Inc. Antibodies to M-CSF
JP2011083291A (ja) * 2003-09-10 2011-04-28 Warner-Lambert Co Llc Ｍ−ｃｓｆに対する抗体
JP2015147802A (ja) * 2003-09-10 2015-08-20 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー Ｍ−ｃｓｆに対する抗体
JP2013223509A (ja) * 2003-09-10 2013-10-31 Warner-Lambert Co Llc Ｍ−ｃｓｆに対する抗体
US9718883B2 (en) 2003-09-10 2017-08-01 Amgen Fremont Inc. Antibodies to M-CSF
JP2008067710A (ja) * 2003-09-10 2008-03-27 Warner-Lambert Co Llc Ｍ−ｃｓｆに対する抗体
JP2017035103A (ja) * 2003-09-10 2017-02-16 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー Ｍ−ｃｓｆに対する抗体
EP2364732A1 (fr) 2006-03-22 2011-09-14 F. Hoffmann-La Roche AG Traitement antitumoral au moyen d'un anticorps contre le facteur de croissance endothélial vasculaire (vegf) et d'un anticorps contre le récepteur humain du facteur de croissance épitheliale de type 2 (her2)
EP2441472A1 (fr) 2006-08-21 2012-04-18 F. Hoffmann-La Roche AG Thérapie de tumeur avec anticorps anti-VEGF
US10927163B2 (en) 2007-12-21 2021-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US10138293B2 (en) 2007-12-21 2018-11-27 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US9708396B2 (en) 2008-10-08 2017-07-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
EP2781526A1 (fr) 2008-10-08 2014-09-24 F. Hoffmann-La Roche AG Anticorps bispécifiques anti-VEGF/anti-ANG-2
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
EP2792687A1 (fr) 2008-10-08 2014-10-22 F. Hoffmann-La Roche AG Anticorps bispécifiques anti-VEGF/anti-ANG-2
US8703130B2 (en) 2008-10-08 2014-04-22 Hoffmann-La Roche, Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
US9382323B2 (en) 2009-04-02 2016-07-05 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
US9890204B2 (en) 2009-04-07 2018-02-13 Hoffmann-La Roche Inc. Trivalent, bispecific antibodies
US10640555B2 (en) 2009-06-16 2020-05-05 Hoffmann-La Roche Inc. Bispecific antigen binding proteins
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US11673945B2 (en) 2009-06-16 2023-06-13 Hoffmann-La Roche Inc. Bispecific antigen binding proteins
US9994646B2 (en) 2009-09-16 2018-06-12 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
WO2011117329A1 (fr) 2010-03-26 2011-09-29 F. Hoffmann-La Roche Ag Anticorps bispécifiques, bivalents anti-vegf/anti-ang-2
US8945552B2 (en) 2010-03-26 2015-02-03 Hoffmann-La Roche Inc. Bispecific, bivalent anti-VEGF/anti-ANG-2 antibodies
US10106600B2 (en) 2010-03-26 2018-10-23 Roche Glycart Ag Bispecific antibodies
WO2012022747A1 (fr) 2010-08-17 2012-02-23 F. Hoffmann-La Roche Ag Thérapie de combinaison d'un anticorps afucosylé anti-cd20 avec un anticorps anti-vegf
US9879095B2 (en) 2010-08-24 2018-01-30 Hoffman-La Roche Inc. Bispecific antibodies comprising a disulfide stabilized-Fv fragment
US11618790B2 (en) 2010-12-23 2023-04-04 Hoffmann-La Roche Inc. Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
US9982036B2 (en) 2011-02-28 2018-05-29 Hoffmann-La Roche Inc. Dual FC antigen binding proteins
US10611825B2 (en) 2011-02-28 2020-04-07 Hoffmann La-Roche Inc. Monovalent antigen binding proteins
US10793621B2 (en) 2011-02-28 2020-10-06 Hoffmann-La Roche Inc. Nucleic acid encoding dual Fc antigen binding proteins
US9688758B2 (en) 2012-02-10 2017-06-27 Genentech, Inc. Single-chain antibodies and other heteromultimers
US10106612B2 (en) 2012-06-27 2018-10-23 Hoffmann-La Roche Inc. Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
US11421022B2 (en) 2012-06-27 2022-08-23 Hoffmann-La Roche Inc. Method for making antibody Fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
US11407836B2 (en) 2012-06-27 2022-08-09 Hoffmann-La Roche Inc. Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
US10683345B2 (en) 2012-07-13 2020-06-16 Roche Glycart Ag Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases
US9695233B2 (en) 2012-07-13 2017-07-04 Roche Glycart Ag Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases
US9567403B2 (en) 2013-08-06 2017-02-14 Bio-Thera Solutions, Ltd. Bispecific antibodies which bind EGFR and VEGF
US10323099B2 (en) 2013-10-11 2019-06-18 Hoffmann-La Roche Inc. Multispecific domain exchanged common variable light chain antibodies
US10633457B2 (en) 2014-12-03 2020-04-28 Hoffmann-La Roche Inc. Multispecific antibodies
WO2019129677A1 (fr) 2017-12-29 2019-07-04 F. Hoffmann-La Roche Ag Anticorps anti-vegf et procédés d'utilisation
US11820816B2 (en) 2017-12-29 2023-11-21 Hoffman-La Roche Inc. Anti-VEGF antibodies and methods of use

Also Published As

Publication number Publication date
AU1687500A (en) 2000-07-03

Similar Documents

Publication Publication Date Title
WO2000035956A1 (fr) Anticorps monoclonal anti-vegf humain
JP3946256B2 (ja) ヒトインターロイキン５受容体α鎖に対する抗体
US7615215B2 (en) Anti-human VEGF receptor Flt-1 monoclonal antibody
JP5631733B2 (ja) 抗ＥｐＣＡＭ抗体およびその使用
WO1999059636A1 (fr) Inhibiteurs de l'activite du facteur de croissance endothelial vasculaire (vegf)
WO2007142277A1 (fr) Anticorps monoclonal capable de se lier au facteur de croissance de type facteur de croissance épidermique se liant à l'héparine
KR102486507B1 (ko) 플렉틴-1 결합 항체 및 그의 용도
KR20120118918A (ko) 인간화 항-ｅｍａｐｉｉ 항체 및 이의 용도
WO2021213466A1 (fr) Anticorps anti-cd73 et son utilisation
WO1999040118A1 (fr) Anticorps diriges contre le recepteur kdr humain du vegf
US6639057B1 (en) Monoclonal antibody against human telomerase catalytic subunit
AU767731B2 (en) Gene recombinant antibodies
WO2022083723A1 (fr) Anticorps anti-cd73 et son utilisation
US20030175271A1 (en) VEGF activity inhibitor
CN113121689B (zh) Ctla-4结合分子及其用途
CN114656566A (zh) 一种靶向cd47的抗体及其应用
JP2001046066A (ja) 新規な相補性決定領域を有するヒトｖｅｇｆ受容体ｋｄｒに対する抗体
JP3679406B2 (ja) 遺伝子組換え抗体
WO2001023573A1 (fr) Anticorps transplantes a domaine de determination de complementation de type humain, dresse contre le ganglioside gd2, et derive de cet anticorps
CN111018988B (zh) 一种抗cd19的抗体、制备方法及其应用
CN108659128B (zh) 抗cd19蛋白的单克隆抗体及其细胞株、制备方法和应用
KR102662387B1 (ko) B7-h3 항체, 이의 항원-결합 단편 및 이의 의학적 용도
JP2003310275A (ja) ヒトインスリン様成長因子に対する遺伝子組換え抗体
JP2003261460A (ja) 肺選択的癌転移の診断薬および治療薬
WO1999048926A1 (fr) ANTICORPS DIRIGE CONTRE LA α1,3-FUCOSYLTRANSFERASE (Fuc-TVII) HUMAINE

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 2000 16875

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 588212

Kind code of ref document: A

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase